

Neoadjuvant chemo response predicts sinonasal SCC outcomes

March 8 2016



(HealthDay)—For patients with sinonasal squamous cell carcinoma

(SCC), pathologic response to neoadjuvant chemotherapy is associated with disease progression, according to a study published online March 2 in *Head & Neck*.

Hitoshi Hirakawa, M.D., Ph.D., from the Aichi Cancer Center Hospital in Nagoya, Japan, and colleagues performed surgery on 58 patients with sinonasal SCC, including 43 patients who had received [neoadjuvant chemotherapy](#). The pathological response was classified as grade 0, 1, 2, and 3 (no, slight, moderate, and marked effect, respectively), and the correlation for pathological response with prognosis was examined.

The researchers found that 34.9 percent of cases that received neoadjuvant chemotherapy had grade 2 or 3 response. The effective neoadjuvant chemotherapy group (grades 2 and 3 response) had significantly better overall survival, disease-free survival, locoregional control, and freedom from distant metastasis than the less effective neoadjuvant chemotherapy group (grades 0 and 1) and the non-neoadjuvant chemotherapy group combined.

"Pathological response to neoadjuvant chemotherapy in sinonasal SCC was related to disease prognosis," the authors write.

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2016 [HealthDay](#). All rights reserved.

Citation: Neoadjuvant chemo response predicts sinonasal SCC outcomes (2016, March 8) retrieved 10 April 2024 from <https://medicalxpress.com/news/2016-03-neoadjuvant-chemo-response-sinonasal-scc.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private

study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.